Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline

Project Information

RespiriNTM

Grant agreement ID: 853932

DOI 10.3030/853932

EC signature date 8 May 2019

Start date 1 May 2019

End date 30 April 2027

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 16 009 225,82

EU contribution € 5 687 983,75

Coordinated by

ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (6)

In vitro activity of single HDT compounds report

In vitro activity of single HDT compounds report will summarize the results of in vitro activity of single Host Directed Therapeutics compounds against intracellular NTM strains in human cells

Zebrafish in vivo test report

The Zebrafish in vivo test report will summarize the methodology and results of the efficacy against known tuberculosis compounds and the effect on granuloma testing in zebrafish larvae for individual NTM compounds

Human NTM in vitro infection Model report

The Human NTM in vitro infection Model report will describe the methodology and assay conditions for an in vitro infection model for NTM (M. avium) in human cells

Purified NTM cytochrome report

The Purified NTM cytochrome report will describe the methodology and confirmation of the biological structures of the purified cytochrome bc1, bc1:aa3, and bd

NTM drug PK report

NTM drug PK report will describe the methodology used and describe the PK model of the NTM drugs

Enzymatic Assay and Characterization of cyt bc1 & bd inhibitors report

The Enzymatic Assay and Characterization of cyt bc1 & bd inhibitors report will describe the assay, conditions and characterisation methodology of the enzymatic assay for testing cytochrome bc1 and cytochrome bd inhibitors

Websites, patent fillings, videos etc. (1)

Website RESPIRI- NTM online

The website developped for communication of all RespiriNTM activities will be active and online

Publications

Peer reviewed articles (4)

Specificity of the innate immune responses to different classes of non-tuberculous mycobacteria

Author(s): Wanbin Hu, Bjørn E. V. Koch, Gerda E. M. Lamers, Gabriel Forn-Cuní, Herman P. Spaink
Published in: Frontiers in Immunology, 2023, ISSN 1664-3224
Publisher: Frontiers Media S.A
DOI: 10.3389/fimmu.2022.1075473

Modeling nontuberculous mycobacterial infections in zebrafish

Author(s): Matt D. Johansen Herman P. Spaink Stefan H. Oehlers Laurent Kremer
Published in: Trends in Microbiology, 2023, ISSN 1878-4380
Publisher: Cell Press
DOI: 10.1016/j.tim.2023.11.011

Host- directed therapy to combat mycobacterial infections

Author(s): Gül Kilinç, Anno Saris, Tom H. M. Ottenhoff, Mariëlle C. Haks
Published in: Immunological Reviews, Issue 01052896, 2021, Page(s) 62-83, ISSN 0105-2896
Publisher: Blackwell Publishing Inc.
DOI: 10.1111/imr.12951

Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium

Author(s): Gül Kilinç, Kimberley V. Walburg, Kees L. M. C. Franken, Merel L. Valkenburg, Alexandra Aubry, Mariëlle C. Haks, Anno Saris1, Tom H. M. Ottenhoff
Published in: Frontiers in Cellular and Infection Microbiology, 2022, ISSN 2235-2988
Publisher: Frontiers Media S. A.
DOI: 10.3389/fcimb.2022.872361